PROSTAID Calgary announces that guest speaker Christine Hentschel of Calgary Meals on Wheels will be featured at its March 18 meeting. The free session will discuss nutrition challenges faced by ...

Having survived the cancer which took his father, Graham Heron, from Bovington, is urging more men to act quickly to avoid falling victim to the most common cancer affecting men in the UK.

Bob Dole appeared in its commercials in the '90s, before the blue pill with a funny name entered the public lexicon, impotence was hush-hush. Now there's no getting away from it. In-boxes are clogged ...

Heaven’s Beverley Mitchell reflected on a life-changing experience when doctors found the “biggest precancerous polyp” on her ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and ...

This article was reviewed by Darragh O’Carroll, MD. Key takeaways: Testosterone cream is a needle-free testosterone therapy that can effectively raise hormone levels. Benefits include improved ...

Profound Medical Corp. (NASDAQ:PROF) Q4 2025 Earnings Call Transcript March 6, 2026 Operator: Good day, and thank you for ...

Researchers at the National University of Singapore (NUS) have identified a protein called tyrosine phosphatase 1B (PTP1B) as a potential "switch" that can modulate a type of cancer cell death known ...

Scientists have reported results from an early-stage trial of an immunotherapy drug called VIR-5500. The drug offers new hope for men with advanced prostate cancer who have stopped responding to other ...

Oxybutynin significantly reduced hot flash frequency and severity compared with placebo among men with prostate cancer ...